Top Story

Blood donors do not transmit neurodegenerative diseases to transfusion recipients

September 30, 2016

Patients who receive blood transfusions from donors who later develop neurodegenerative disorders are at low to no risk for the transmission of these diseases, according to a retrospective cohort study published in Annals of Internal Medicine.

The aggregation of aberrantly polymerized, misfolded proteins in the brain occurs with several neurodegenerative disorders, including Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis (ALS) and other dementia-related disorders. Further, protein aggregation has been found to have similarities with prion diseases.

Seven updates in thyroid cancer

September 30, 2016
Thyroid Cancer Awareness month has been observed worldwide since its initiation in 2000 by the Thyroid Cancer Survivors’ Association. HemOnc Today
In the Journals

Majority of adverse events in clinical trials remain unpublished

September 30, 2016
A lower number and smaller range of adverse events were reported in published studies compared with those unpublished, according to data published in PLoS Medicine

Survey: Americans consider cancer nation's top health care challenge

September 30, 2016
Americans consider cancer the most significant health care challenge in the United States, according to results of the Mayo Clinic National Health Checkup survey. The…
At Issue

Cancer survivors with physical, psychological concerns benefit from team-based approach to care

September 30, 2016
Survivors of breast cancer have “a variety of concerns” following completion of treatment, according to Charles L. Shapiro, MD, of the Icahn School of
More News Headlines »

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Meeting News Coverage

VIDEO: Less surgery, active surveillance viable option for low-risk thyroid cancer

September 22, 2016
More »

Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going

This activity is supported by an educational grant from Genentech.

Melanoma is the deadliest form of skin cancer. Historically, treatment options have been limited for patients with…
More »
Current Issues
View the Current Issue
HemOnc Today